Stocks and Investing Stocks and Investing
Fri, June 24, 2022
Thu, June 23, 2022
Wed, June 22, 2022
Tue, June 21, 2022

David Macdonald Maintained (AMED) at Strong Buy with Decreased Target to $175 on, Jun 21st, 2022


Published on 2024-10-27 21:34:10 - WOPRAI, David Macdonald
  Print publication without navigation


David Macdonald of Truist Securities, Maintained "Amedisys, Inc." (AMED) at Strong Buy with Decreased Target from $200 to $175 on, Jun 21st, 2022.

David has made no other calls on AMED in the last 4 months.



There are 6 other peers that have a rating on AMED. Out of the 6 peers that are also analyzing AMED, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Andrew Mok of "UBS" Upgraded from Strong Sell to Hold and Increased Target to $168 on, Tuesday, March 1st, 2022


These are the ratings of the 5 analyists that currently disagree with David


  • A.J. Rice of "Credit Suisse" Maintained at Buy with Increased Target to $182 on, Friday, April 29th, 2022
  • John Ransom of "Raymond James" Maintained at Buy with Decreased Target to $180 on, Friday, April 29th, 2022
  • Matt Borsch of "BMO Capital" Upgraded from Hold to Buy and Held Target at $190 on, Friday, February 25th, 2022
  • Michael Wiederhorn of "Oppenheimer" Maintained at Buy with Decreased Target to $200 on, Friday, February 25th, 2022
  • Bill Sutherland of "Benchmark" Maintained at Strong Buy with Decreased Target to $175 on, Thursday, February 24th, 2022